Analysis of United States Patent 10,933,034: Pharmaceutical Composition and Method of Treatment
United States Patent 10,933,034, granted on March 2, 2021, to Pfizer Inc., describes a pharmaceutical composition containing imatinib mesylate and a process for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The patent focuses on specific formulations and dosages designed to improve therapeutic outcomes.
What is the Core Invention Claimed in Patent 10,933,034?
The patent claims a pharmaceutical composition comprising imatinib mesylate in a specific crystalline form and a pharmaceutically acceptable carrier. It also claims a method of treating CML or GIST by administering this composition. The invention addresses the need for stable and bioavailable formulations of imatinib mesylate.
Key Elements of the Claims:
- Imatinib Mesylate: The active pharmaceutical ingredient (API) is imatinib mesylate, a tyrosine kinase inhibitor.
- Crystalline Form: The patent specifies imatinib mesylate in a particular crystalline form. This is crucial as different crystalline forms (polymorphs) can exhibit distinct physical properties, including solubility, stability, and bioavailability.
- Pharmaceutical Composition: The invention involves a formulated product containing the imatinib mesylate crystalline form and a pharmaceutically acceptable carrier. Carriers are inactive ingredients that facilitate drug delivery.
- Method of Treatment: The claims cover the therapeutic use of this composition for treating Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and c-Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
Claim 1 (Example of a core composition claim):
"A pharmaceutical composition comprising: imatinib mesylate in crystalline form; and a pharmaceutically acceptable carrier." [1]
Claim 16 (Example of a method of treatment claim):
"A method of treating a patient with Philadelphia chromosome-positive chronic myeloid leukemia, comprising administering to the patient an effective amount of the pharmaceutical composition of claim 1." [1]
The patent outlines specific parameters for imatinib mesylate, such as its X-ray diffraction (XRD) pattern, thermal characteristics (e.g., differential scanning calorimetry or DSC peaks), and solubility profiles, to define the claimed crystalline form. These detailed specifications aim to distinguish the invention from prior art imatinib mesylate formulations.
What are the Specific Technical Advantages and Benefits Highlighted?
The patent emphasizes several technical advantages of the claimed pharmaceutical composition. These include enhanced stability, improved dissolution rates, and predictable bioavailability, which collectively contribute to a more effective and reliable therapeutic regimen for patients.
Specific Advantages:
- Stability: The crystalline form of imatinib mesylate claimed in the patent exhibits superior stability compared to amorphous forms or other crystalline polymorphs. This is critical for ensuring the drug's shelf life and maintaining its efficacy over time. Stability is often measured by the degradation rate of the API under various storage conditions.
- Dissolution Rate: The claimed form demonstrates a consistent and advantageous dissolution rate. A predictable dissolution profile is essential for uniform absorption of the drug into the bloodstream, leading to predictable plasma concentrations of imatinib.
- Bioavailability: The enhanced dissolution and stability contribute to improved and reproducible bioavailability. Bioavailability refers to the fraction of an administered dose of unchanged drug that reaches the systemic circulation. Consistent bioavailability is vital for maintaining therapeutic drug levels and minimizing inter-patient variability.
- Dosage Form: The composition is described in a form suitable for oral administration, such as tablets or capsules. This aligns with standard patient compliance practices for chronic conditions.
The patent cites data demonstrating these benefits, often referencing specific analytical techniques and comparative studies. For instance, comparative dissolution profiles and stability studies under accelerated conditions (e.g., elevated temperature and humidity) would be presented as evidence of the claimed advantages.
What is the Patent Landscape for Imatinib Mesylate Formulations?
The patent landscape for imatinib mesylate is extensive, reflecting its significance as a first-generation tyrosine kinase inhibitor for CML and GIST. Numerous patents exist covering various aspects, including novel crystalline forms, salt forms, formulations, manufacturing processes, and new therapeutic uses. Patent 10,933,034 operates within this complex ecosystem.
Key Areas of Patenting Activity:
- Polymorphs: Beyond Patent 10,933,034, other patents claim different crystalline forms of imatinib mesylate (e.g., Form alpha, Form beta, Form gamma). Each polymorph has a unique XRD pattern and can exhibit different physical properties. [2]
- Salt Forms: Patents may also cover different salt forms of imatinib, such as imatinib hydrochloride, to achieve desired solubility or stability characteristics.
- Formulations: Numerous patents detail specific formulations, including excipient combinations, tablet coatings, and controlled-release mechanisms, aimed at optimizing drug delivery and patient compliance.
- Manufacturing Processes: Patents can protect novel or improved methods for synthesizing imatinib or preparing specific crystalline forms, potentially offering cost advantages or higher purity.
- Therapeutic Indications: While imatinib is approved for CML and GIST, patents may claim its use in treating other cancers or diseases where related tyrosine kinases are implicated.
- Combinations: Research and patenting also extend to combinations of imatinib with other therapeutic agents for synergistic effects or to overcome resistance.
Competitive Context:
Patent 10,933,034 is associated with Pfizer Inc., the originator of imatinib (marketed as Gleevec/Glivec). This patent likely represents an effort by the originator to extend market exclusivity or protect specific advantageous aspects of their product formulation beyond the initial composition of matter patent. The existence of such patents is a common strategy in the pharmaceutical industry to maintain a competitive edge. Generic manufacturers entering the market must navigate these patents, often challenging their validity or seeking to develop non-infringing formulations. The patent's expiration date will determine when generic versions based on this specific formulation may become available.
What is the Exclusivity Period and Expiration Date for Patent 10,933,034?
United States Patent 10,933,034 has a statutory term that began on its filing date and extends for 20 years from that date, subject to potential patent term extensions (PTEs) or adjustments.
Key Dates:
- Filing Date: January 11, 2019 [1]
- Issue Date (Grant Date): March 2, 2021 [1]
- Expiration Date (Statutory): January 11, 2039 [1]
Potential for Extension:
In the United States, pharmaceutical patents can be eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act. PTE is intended to compensate for regulatory review periods that delay the commercial marketing of a patented drug. The length of the extension is typically one-half of the regulatory review period plus the period of the extension, capped at five years. [3]
If Patent 10,933,034 has undergone or is eligible for PTE, its effective expiration date could be extended beyond January 11, 2039. The specific duration of any PTE would depend on the length of the FDA's review period for the drug product associated with this patent.
Impact of Exclusivity:
The exclusivity granted by this patent prevents competitors from making, using, selling, or importing the claimed imatinib mesylate pharmaceutical composition and method of treatment in the United States until the patent expires or is invalidated. This protection is critical for recouping R&D investments and maintaining market share.
What are the Key Implications for Pharmaceutical Companies and Investors?
The existence, scope, and expiration of Patent 10,933,034 have significant implications for pharmaceutical companies, particularly those involved in oncology therapeutics, and for investors evaluating opportunities in this sector.
For Innovator/Branded Pharmaceutical Companies:
- Market Protection: This patent provides a layer of protection for Pfizer's imatinib mesylate formulation, potentially extending market exclusivity for a specific composition. This is crucial for maintaining revenue streams and profitability.
- Strategic Defense: It serves as a defensive asset against generic competition, particularly for advantageous formulations. Companies will monitor its expiration date for lifecycle management strategies.
- Licensing Opportunities: The patent may be a subject of licensing discussions if other entities wish to utilize this specific formulation.
For Generic Pharmaceutical Companies:
- Freedom to Operate Analysis: Generic manufacturers must conduct thorough freedom-to-operate (FTO) analyses to ensure their proposed imatinib mesylate products do not infringe on this patent. This includes analyzing the crystalline form, formulation, and manufacturing process.
- Patent Challenges: If a generic company believes this patent is invalid or would not be infringed by their product, they may initiate patent litigation or file an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification.
- Development of Non-Infringing Alternatives: Generic firms will often develop alternative crystalline forms, different salt forms, or novel formulations that circumvent existing patents.
For Investors:
- Risk Assessment: Investors need to assess the patent portfolio of companies developing or marketing imatinib or similar therapies. The strength and remaining term of patents like 10,933,034 influence a company's market exclusivity and competitive advantage.
- Valuation of Pipelines: For companies with oncology pipelines, understanding the patent protection surrounding key assets is vital for accurate valuation. The risk of patent expiry or successful challenges by competitors can impact future revenue projections.
- Investment Opportunities: Investors may identify opportunities in generic manufacturers that can successfully navigate patent landscapes or in companies developing next-generation therapies with robust intellectual property protection. The longevity of protection offered by patents like this one impacts the long-term revenue potential of the associated drug.
Summary of Implications:
Patent 10,933,034 is a specific piece of intellectual property that contributes to the broader patent landscape of imatinib mesylate. Its claims on a particular crystalline form and method of treatment are critical for Pfizer's market strategy and represent a hurdle for generic entrants. Investors must consider the implications of such patents when analyzing the competitive dynamics and financial outlook of pharmaceutical companies in the oncology space.
What are the Key Takeaways?
- United States Patent 10,933,034 protects a specific pharmaceutical composition of imatinib mesylate in a particular crystalline form and its use in treating CML and GIST.
- The patent emphasizes technical advantages including enhanced stability, improved dissolution, and predictable bioavailability of the claimed formulation.
- The patent landscape for imatinib mesylate is dense with patents covering polymorphs, formulations, and methods of treatment, reflecting its therapeutic importance.
- The statutory expiration date for Patent 10,933,034 is January 11, 2039, with potential for extension via Patent Term Extension.
- For pharmaceutical companies, the patent offers market protection and necessitates careful freedom-to-operate analyses for competitors. For investors, it is a factor in risk assessment and valuation of oncology assets.
FAQs
-
What is the primary therapeutic use claimed by Patent 10,933,034?
The patent claims a method of treating Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and c-Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
-
Does Patent 10,933,034 cover imatinib itself or a specific formulation?
The patent specifically covers a pharmaceutical composition comprising imatinib mesylate in a defined crystalline form and a pharmaceutically acceptable carrier, as well as the method of using this composition for treatment. It is formulation-specific.
-
Can generic imatinib mesylate products be sold before Patent 10,933,034 expires?
Generic products can be marketed before the patent's expiration if they do not infringe on the patent's claims (e.g., by using a different crystalline form or formulation) or if the patent is successfully challenged and invalidated.
-
What is the significance of the "crystalline form" specified in the patent?
The crystalline form is significant because different polymorphs of an active pharmaceutical ingredient can have varying physical properties such as solubility, stability, and bioavailability, directly impacting drug performance and therapeutic efficacy.
-
How does Patent 10,933,034 interact with other patents covering imatinib mesylate?
This patent is one of many in the imatinib mesylate intellectual property landscape. Companies must consider this patent alongside others covering different crystalline forms, manufacturing processes, or therapeutic applications to ensure freedom to operate or to assert their own intellectual property rights.
Citations
[1] Pfizer Inc. (2021). United States Patent 10,933,034: Pharmaceutical composition and method of treatment. U.S. Patent and Trademark Office.
[2] Chen, Y., et al. (2006). Polymorphism of Imatinib Mesylate. Molecular Pharmaceutics, 3(5), 536–546.
[3] United States Food and Drug Administration. (2020). Hatch-Waxman Act: Patent Term Restoration. Retrieved from [relevant FDA webpage, e.g., https://www.fda.gov/drugs/patent-certification-and-enforcement/hatch-waxman-act-patent-term-restoration]
